Matrix Pharmaceutical Inc.

The progress of Esteve's lead compound Surfaxin illustrates how the Spanish group is building a robust, yet risk-controlled pipeline to supplement its co-marketing activities. The compound may also be

At the top of the industry, consolidation has frozen out much additional M[TKTK] at the bottom—particularly in biotech—consolidation usually provides more problems than answers. By Roger Longman If yo

It's clearly a buyer's market in the public biotech sector. On the shopping list: products, chemistry, and cash. Triangle Pharmaceuticals Inc. is one of the relatively fortunate acquirees. In Novem

Genta and Aventis are working to commercialize Genasense for cancer. As befits their respective size and scope, the firms have different approaches to managing the risks of novelty. by Deborah Erickso